Keywords: AVEO Oncology, Astellas, Tivozanib, Kidney cancer, USA, FDA, Renal cell carcinoma, NDA, VEGF

AVEO and Astellas file NDA for tivozanib in kidney cancer

Article | 02 October 2012

Print This

USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted a New Drug Application to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in